Publicaciones en las que colabora con Oscar Briz Sánchez (27)

2022

  1. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

    Hepatology, Vol. 76, Núm. 5, pp. 1259-1274

  2. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

    Cancers, Vol. 14, Núm. 14

  3. Impact of Liver Inflammation on Bile Acid Side Chain Shortening and Amidation

    Cells, Vol. 11, Núm. 24

2020

  1. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment

    Cancers, Vol. 12, Núm. 9, pp. 1-34

  2. Molecular bases of drug resistance in hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 6, pp. 1-26

  3. Role of genetic variations in the hepatic handling of drugs

    International Journal of Molecular Sciences, Vol. 21, Núm. 8

2019

  1. Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy

    Hepatology, Vol. 70, Núm. 4, pp. 1246-1261

  2. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps

    Archives of Toxicology, Vol. 93, Núm. 3, pp. 623-634

  3. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

2018

  1. Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 9, pp. 2927-2937

2017

  1. ACOX2 deficiency: An inborn error of bile acid synthesis identified in an adolescent with persistent hypertransaminasemia

    Journal of Hepatology, Vol. 66, Núm. 3, pp. 581-588

2016

  1. Bile acids in physiology, pathology and pharmacology

    Current Drug Metabolism, Vol. 17, Núm. 1, pp. 4-29

  2. Protective role of biliverdin against bile acid-induced oxidative stress in liver cells

    Free Radical Biology and Medicine, Vol. 97, pp. 466-477

2015

  1. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)

    Journal of Controlled Release, Vol. 216, pp. 93-102

2014

  1. Cocarcinogenic effects of intrahepatic bile acid accumulation in cholangiocarcinoma development

    Molecular Cancer Research, Vol. 12, Núm. 1, pp. 91-100

  2. The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy

    Acta Pharmacologica Sinica, Vol. 35, Núm. 1, pp. 1-10

2013

  1. Genetic Variants Involved in Intracellular Mechanisms of Chemoresistance to Anticancer Drugs Due to Changes in the Effect on Their Molecular Targets

    eLS

2012

  1. ABCC2 is involved in the hepatocyte perinuclear barrier for small organic compounds

    Biochemical Pharmacology, Vol. 84, Núm. 12, pp. 1651-1659

  2. Characterization of the role of ABCG2 as a bile acid transporter in liver and placenta

    Molecular Pharmacology, Vol. 81, Núm. 2, pp. 273-283

  3. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs

    Current Cancer Drug Targets, Vol. 12, Núm. 4, pp. 402-438